Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Policy Power Challenged In House Questions On Untitled Letters

This article was originally published in The Pink Sheet Daily

Executive Summary

Chairman Murphy wants to know if FDA is aware of consequences of publishing letters during stock trading hours.

You may also be interested in...

FDA’s Untitled Letter Posting Driven By ‘Significant Public Interest,’ Not Stock Market

Response to congressional inquiry also notes that FDA's policy is not to make policy in untitled letters.

Biosimilar Naming, Interchangeability Policies Must Be Done Soon, House Tells FDA

Appropriations report sets a deadline, but doesn't include a penalty for missing it as the House had with the opioid guidance last year.

FDA’s Twitter Formula Allows Tweets About Products Without Excessive Risks

FDA’s draft guidance on presenting product information on social media platforms with character space limitations includes an equation for sending a tweet.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts